Latest Deals
The partnership between Roche and Poseida began in 2022, focusing on the development of off-the-shelf CAR-T cell therapies. Credit: metamorworks / Shutterstock
Roche to acquire Poseida Therapeutics for $1.5bn
Roche has signed an agreement to acquire Poseida Therapeutics in a $1.5bn deal. The transaction includes Poseida’s clinical and pre-clinical CAR-T therapies and manufacturing capabilities. Roche will begin a tender offer to acquire complete outstanding Poseida common stock shares for $9 per share in cash at closing, along with a non-tradeable contingent value right (CVR) for potential milestone payments of up to an aggregate of $4 per share in cash.
Novartis and Olema expand alliance with $250m to boost breast cancer trials
Olema Oncology has announced another clinical trial collaboration and supply agreement with Novartis for a Phase III trial in metastatic breast cancer, in addition to a $250m private placement to fund ongoing operations and research efforts. Under the collaboration with Novartis, Olema plans to initiate the pivotal Phase III OPERA-02 clinical trial in mid-2025.
Enveda raises $130m to advance AI-driven plant based drug development
Artificial Intelligence (AI)-driven biotech Enveda Biosciences has raised $130m in a Series C funding round to accelerate its drug discovery and development programmes. The funding will enable Enveda to advance its pipeline of ten drug candidates, targeting immunology, obesity, fibrosis, chronic pain, and neurological disorders, with the company planning to achieve clinical catalysts in 2025 and 2026.
Adcendo raises $135m as ADC funding frenzy continues
Acadia Pharmaceuticals has secured an exclusive global licence from Saniona to develop and commercialise SAN711 for essential tremor, a neurological disorder characterised by involuntary shaking. A new GABAA-α3 positive allosteric modulator, SAN711 will be investigated in a Phase II study for the indication in 2026.
